Shorla Pharma
Shorla Oncology develops and commercializes innovative oncology drugs, focusing on indications where treatments are limited, in shortage, or inadequate. Their team includes thought leaders, clinicians, scientists, and strategists with extensive experience in drug development and commercialization of niche cancer treatments. Their mission is to improve patient care by bringing accessible, affordable, and life-changing treatments. They aim to re-think and improve existing oncology treatments through research, development, and innovation, with core values of compassion, commitment, innovation, tenacity, and collaboration.
Industries
Nr. of Employees
small (1-50)
Shorla Pharma
Questum Acceleration Center, Ballingarrane Science & Technology Park, Clonmel, Co. Tipperary, E91 V329, Ireland
Patents
Products
Tepylute (ready-to-dilute thiotepa formulation)
Ready-to-dilute sterile formulation of thiotepa intended for oncology indications; provided as a prepared formulation for dilution prior to administration.
Liquid methotrexate formulation (Jylamvo)
Liquid methotrexate product approved for oncology and autoimmune indications, with pediatric approvals for specific indications.
Nelarabine Injection
Injectable formulation of nelarabine for treatment of T-cell leukemia and lymphoma.
Imatinib mesylate (Imkeldi) distribution
Commercial product distribution for an imatinib mesylate formulation referenced in site navigation.
Tepylute (ready-to-dilute thiotepa formulation)
Ready-to-dilute sterile formulation of thiotepa intended for oncology indications; provided as a prepared formulation for dilution prior to administration.
Liquid methotrexate formulation (Jylamvo)
Liquid methotrexate product approved for oncology and autoimmune indications, with pediatric approvals for specific indications.
Nelarabine Injection
Injectable formulation of nelarabine for treatment of T-cell leukemia and lymphoma.
Imatinib mesylate (Imkeldi) distribution
Commercial product distribution for an imatinib mesylate formulation referenced in site navigation.
Services
Design and execution of market access strategies, sales force deployment, and partnerships to support product launches in target markets.
Negotiation and execution of licensing agreements and strategic partnerships to obtain marketing rights or co-commercialize oncology medicines.
Use of third-party commercialization partners to support product launch and distribution.
Design and execution of market access strategies, sales force deployment, and partnerships to support product launches in target markets.
Negotiation and execution of licensing agreements and strategic partnerships to obtain marketing rights or co-commercialize oncology medicines.
Use of third-party commercialization partners to support product launch and distribution.
Expertise Areas
- Clinical trial management and clinical development
- Formulation development for oral and parenteral oncology products
- Regulatory strategy and FDA submission pathways
- Commercialization and market access
Key Technologies
- Oral suspension formulation
- Ready-to-dilute sterile injectable formulation
- Multidose vial presentations
- Formulation optimization for palatability (pediatric focus)
News & Updates
FDA has granted orphan drug designation to SH-110 for treating Glioma.
The FDA has granted orphan status to the liquid glioma treatment SH-110.
The FDA has granted orphan drug designation to SH-110 for oral suspension in glioma.
The FDA has granted fast track designation to an oral liquid for brain cancer.
The FDA has granted orphan drug designation to SH-110, a liquid glioma therapy.
The FDA has granted orphan drug designation to SH-110 for treating rare brain cancer.
FDA has granted orphan drug designation to SH-110 for treating Glioma.
The FDA has granted orphan status to the liquid glioma treatment SH-110.
The FDA has granted orphan drug designation to SH-110 for oral suspension in glioma.
The FDA has granted fast track designation to an oral liquid for brain cancer.
The FDA has granted orphan drug designation to SH-110, a liquid glioma therapy.
The FDA has granted orphan drug designation to SH-110 for treating rare brain cancer.